MindMaze Therapeutics Sells Non-Core Assets to Refocus on Neurology

MindMaze Therapeutics Holding SA, a leader in precision neurotherapeutics, announced the sale of its U.S. and Canadian rights to RLF-OD032, a program for phenylketonuria. This move aligns with the company's strategy to dispense with non-core assets and concentrate on its core neurology focus. MindMaze will receive $3 million upfront and royalties on future sales of RLF-OD032.

The company is also in the process of divesting remaining non-neurology operations acquired through its merger with Relief Therapeutics. These steps, part of a portfolio review, aim to streamline operations, boost focus, and cut costs by about a third. The reorganization is anticipated to finalize by the third quarter of 2026, focusing resources on neurology, including commercial and patient access expansion.